- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07944079
Acupuncture Delivery In The Clinical Decision Unit (CDU) For The Management Of Pain, Nausea, And Other Symptoms
The overall goal of this research is to improve the management of distressing symptoms, specifically nausea and pain, in cancer patients within the acute care setting of the CDU at MD Anderson.
Studie Overzicht
Gedetailleerde beschrijving
Primary Objectives and Endpoints:
Determine the feasibility of an operational protocol of providing acupuncture treatment for nausea and/or pain in the CDU at MD Anderson Cancer Center. Feasibility will be assessed by the proportion of eligible patients who consent to and receive at least one acupuncture treatment. Successful feasibility will be defined as at least 50% of the eligible patients approached consenting and receiving at least one acupuncture session.
Secondary Objectives and Endpoints:
- Examine changes in pain and nausea reported in cancer patients after a single session of acupuncture in the CDU. Preliminary efficacy will be evaluated by having patients complete the ESAS symptom severity before and after each acupuncture session.
- Examine changes in other symptoms assessed on the ESAS after a single session of acupuncture in the CDU. Individual items will be explored as well as global (all symptoms), physical (drowsiness, nausea, pain, shortness of breath, poor appetite, fatigue), and psychological distress (anxiety and depression) subscales.
- Explore the safety profile of providing acupuncture in the CDU. Data will be collected to systematically document and grade any adverse events related to the acupuncture treatment according to the Common Terminology Criteria for Adverse Events (CTCAE) v6.0.
- Explore the patient experience with acupuncture in the CDU. Patients will be asked about their satisfaction with acupuncture, whether they believe it was helpful to reduce their symptoms, if they would use the service again, and if they would recommend acupuncture to others in the CDU. An additional open-ended question will allow patients to make recommendations for future program or service offerings. Satisfaction will be administered to all study participants after each treatment.
- Explore the CDU staff experience with acupuncture in the CDU. The primary clinician assigned to the patient will be asked about their satisfaction with the use of acupuncture for the patient. They will be asked about the logistics of delivering acupuncture and if they perceive any benefit for the patient from before to after in terms of pain, nausea, or anxiety.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Maxine De La Cruz, MD
- Telefoonnummer: 713-563-4419
- E-mail: mgde@mdanderson.org
Studie Locaties
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- UT MD Anderson
-
Contact:
- Maxine De La Cruz, MD
- Telefoonnummer: 713-563-4419
- E-mail: mgde@mdanderson.org
-
Hoofdonderzoeker:
- Maxine De La Cruz, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Adult patients (aged ≥18 years)
- Presenting with a primary complaint of nausea and/or pain
- ESAS nausea and/or pain score of at least 2
- Admitted to the CDU for observation and management of nausea and/or pain.
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
- History of a bleeding disorder
- Coagulation profile with an INR > 2.0 and/or PTT > 90 seconds
- Initiation of anticoagulation for venous thrombosis within the last 24 hours or not yet at a therapeutic dose
- Evidence of bowel obstruction on imaging
- Platelet count < 25,000/uL
- Absolute Neutrophil Count (ANC) < 1.0 K/uL
- Delirium or cognitive impairment in the opinion of the primary CDU physician that limits the ability to follow instructions or provide informed consent.
- Pregnant patients for whom the treating physician or acupuncturist determines acupuncture is not clinically appropriate.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Treatment with Acupuncture
Participants to recruit from are those participants who are admitted into the CDU at UT MD Anderson. |
Treatment will be administered at the participant's bedside in CDU. Needles will remain in place for 20-25 minutes with each treatment. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Safety and Adverse Events (AEs)
Tijdsspanne: Through study completion; an average of 1 year
|
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 6.0 |
Through study completion; an average of 1 year
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Maxine De La Cruz, MD, UT MD Anderson
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2026-0644
- NCI-2026-08619 (Andere identificatie: NCI-CTRP Clinical Trials Registry)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .